SCHEMBL6715790

SCHEMBL6715790

C/C(=N/Nc1ccccn1)c1ccccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 2/20 0.67
KMT2A Q03164 6/20 0.61
GAA P10253 6/20 0.61
MAPT P10636 6/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
RAB9A P51151 5/20 0.61
NPC1 O15118 5/20 0.61
MEN1 O00255 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
ALDH1A1 P00352 1/20 0.61
ALOX12 P18054 1/20 0.61
GFER P55789 1/20 0.61
KDM4E B2RXH2 3/20 0.58
HTT P42858 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TOP2A P11388 2/20 0.56
HSP90AA1 P07900 2/20 0.56
LMNA P02545 1/20 0.56
OPRK1 P41145 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715793 1.00 PAX8 (0.67) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL20101085 1.00 PAX8 (0.67) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL20101020 0.86 PAX8 (0.59) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL20101022 0.85 PAX8 (0.65) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL20101025 0.84 KMT2A (0.64) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL31237795 0.84 KDM4E (0.68) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL14540616 0.83 KMT2A (0.75) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL28153216 0.83 KMT2A (0.75) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL20101098 0.83 MAPT (0.73) PAX8KMT2AGAAMAPTSMN1; SMN2
SCHEMBL1973299 0.82 RAB9A (0.59) PAX8KMT2AGAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US claimed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US claimed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US claimed
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK PAX8 1430/4885KMT2A 3683/4885GAA 1089/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A PAX8 1051/4885KMT2A 4156/4885GAA 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.